NewsTerpene News

Emerald Health Therapeutics Launches New Fast-Acting Cannabis Spray Products Offering Consumers Significantly Improved Predictability and Control of Effects

SYNC(TM) Nano Fast Action Spray uses nanoemulsion technology to enable rapid onset and shorter duration of effects; the first THC product is in-market, with CBD to follow

TM Nano fast-acting cannabis spray product line. SYNCTM 15 Nano THC Fast Action Spray allows consumers to choose ingestion over inhalation of cannabis while achieving a much more rapid, predictable onset and shorter controlled duration of effects compared to edibles and oils. The sublingual spray’s effects can start in 10-20 minutes and last two to four hours. Emerald has made the first product shipment to Alberta and Saskatchewan, with availability for purchase by consumers expected early this week.” data-reactid=”20″>Vancouver, British Columbia–(Newsfile Corp. – August 31, 2020) –  Emerald Health Therapeutics, Inc. (TSXV: EMH) (OTCQX: EMHTF) (“Emerald”)  has launched the first product in its adult-use SYNCTM Nano fast-acting cannabis spray product line. SYNCTM 15 Nano THC Fast Action Spray allows consumers to choose ingestion over inhalation of cannabis while achieving a much more rapid, predictable onset and shorter controlled duration of effects compared to edibles and oils. The sublingual spray’s effects can start in 10-20 minutes and last two to four hours. Emerald has made the first product shipment to Alberta and Saskatchewan, with availability for purchase by consumers expected early this week.

“We looked carefully at unmet needs in the cannabis marketplace and applied our product development capabilities to create a product line with multiple points of consumer appeal,” said Riaz Bandali, President and CEO of Emerald. “With an emphasis on science-based innovation, we created this product line using proven nanoemulsion technology and are pleased to offer the benefits of this high-performing technology to the cannabis industry.”

The SYNCâ„¢ Nano products are formulated by Emerald using a proprietary process to achieve nano-sized droplets that bypass the digestive system due to their tiny size. This result significantly multiplies bioavailability and absorption of cannabinoids in the body compared to the normal path of ingestion of cannabis edibles and oils – and also compared to conventional emulsion approaches. Nanoemulsions are currently being used safely in the drug delivery, pharmaceutical, cosmetic, and food industries to improve the delivery and stability of ingredients.

Emerald Health Therapeutics, Inc. is committed to cutting-edge cannabis science to create new consumer experiences with distinct recreational, medical and wellness-oriented cannabis and non-cannabis products. With an emphasis on innovation and production excellence, Emerald’s three distinct operating assets are designed to uniquely serve the Canadian marketplace and international opportunities. These assets, all in full production, include: its Metro Vancouver, BC-based greenhouse operation (78,000 square feet) capable of producing organic-certified product; Verdélite, its premium craft cannabis production indoor facility in St. Eustache, Québec (88,000 square foot); and Pure Sunfarms, its 41.3%-owned joint venture in Delta, BC, producing high quality, affordably priced products (1.1 M square feet).

www.emeraldhealth.ca for more information or contact:

Jenn Hepburn, Chief Financial Officer
(800) 757 3536 Ext. #5″ data-reactid=”31″>Please visit www.emeraldhealth.ca for more information or contact:

Jenn Hepburn, Chief Financial Officer
(800) 757 3536 Ext. #5

invest@emeraldhealth.ca” data-reactid=”32″>Emerald Investor Relations
(800) 757 3536 Ext. #5
invest@emeraldhealth.ca

Story continues

https://www.newsfilecorp.com/release/62848” data-reactid=”48″>To view the source version of this press release, please visit https://www.newsfilecorp.com/release/62848

Source link

Tags
Show More

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Close